Months 6-12 and Beyond: Long-Term Progress Extended use allows for continued slow progress in body composition
The Third French Individual and National Food Consumption (INCA3) Survey 2014-2015: method, design and participation rate in the framework of a European harmonization process
(PubMed) Poly C, Massaro JM, Seshadri S, et al
These findings are encouraging but must be interpreted with appropriate caution
Consequently, companies such as Novo Nordisk and Eli Lilly are investing heavily in next-generation formulations, including oral small-molecule GLP-1 receptor agonists such as orforglipron, which aim to expand patient accessibility and therapeutic scope The demand for GLP-1 drugs that address a wider array of metabolic conditions is growing rapidly across global markets, as patients and healthcare providers increasingly seek holistic and effective long-term treatment options for obesity and its comorbidities GLP-1 Receptor Agonists Obesity Drugs Market Dynamics Driver Surging Demand Due to Rising Obesity Prevalence and Enhanced Clinical Outcomes The global surge in obesity rates and associated comorbidities such as type 2 diabetes and cardiovascular diseases is significantly driving demand for GLP-1 receptor agonist drugs as effective medical weight loss therapies For instance, in May 2024, Novo Nordisk announced a USD 4.1 billion expansion in its U.S
These methods are not evaluated in the review itself, but they represent a growing interest in how glutathione can be supported beyond lifestyle and precursors
